KALA BIO
KALA
63 hedge funds and large institutions have $2.27M invested in KALA BIO in 2022 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 22 reducing their positions, and 26 closing their positions.
875% more call options, than puts
Call options by funds: $39K | Put options by funds: $4K
0.01% less ownership
Funds ownership: 0.01% → 0% (-0.01%)
23% less funds holding
Funds holding: 82 → 63 (-19)
55% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 22
58% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 26
93% less capital invested
Capital invested by funds: $33.7M → $2.27M (-$31.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$328K |
| 2 |
E
Ergoteles
New York
|
+$138K |
| 3 |
Goldman Sachs
New York
|
+$97.3K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$59.6K |
| 5 |
Renaissance Technologies
New York
|
+$58.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$15M |
| 2 |
BlackRock
New York
|
-$1.47M |
| 3 |
GL
Graypoint LLC
Albany,
New York
|
-$672K |
| 4 |
State Street
Boston,
Massachusetts
|
-$604K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$319K |
KALA Hedge Fund Activity: Q2 2022 in Review
63 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q2 2022, worth a combined $2.27M — down 93% from $33.7M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of KALA and 11 opened new positions — a net loss of 15 holders — while 22 trimmed existing stakes and 10 added.
The largest buyer was Millennium Management, adding an estimated $328K. The largest seller was RA Capital Management, exiting entirely with an estimated $15M sold.
- 63 institutional investors held KALA BIO (KALA) as of Q2 2022, down from 82 in Q1 2022.
- Funds reported $2.27M of KALA BIO stock for Q2 2022, down 93% quarter-over-quarter.
- 11 funds opened new KALA BIO positions in Q2 2022 and 26 closed out, a net change of -15 holders.
- The largest KALA BIO buyer in Q2 2022 was Millennium Management, an estimated $328K added.
- The largest KALA BIO seller in Q2 2022 was RA Capital Management, an estimated $15M sold.
Based on aggregated 13F filings for Q2 2022.